ClinicalTrialsFinder
CompletedPhase 4ACTRN12607000006448

The Rabeprazole and Esomeprazole Reflux Assessment Trial

A multicentre, double blind, randomised controlled non-inferiority study to compare the number of subjects with gastro-oesophageal reflux disease achieving heartburn and regurgitation symptom resolution after treatment with either Rabeprazole Sodium (PARIET) 20mg, Esomeprazole (NEXIUM) 20mg or Esomeprazole (NEXIUM) 40mg

Sponsor

Janssen-Cilag Pty Ltd

Enrollment

1,908 participants

Start Date

Nov 6, 2006

Study Type

Interventional

Conditions

Gastro-oesophageal reflux disease

Summary

The primary purpose of the TREAT study is to compare the number of subjects in which heartburn and regurgitation symptoms resolve after being treated with either PARIET 20mg, NEXIUM 20mg or NEXIUM 40mg. All 3 medications are commonly prescribed for Gastro-oesophageal Reflux Disease (GORD). It is hypothesised that PARIET 20mg will be non-inferior to NEXIUM 40mg in resolving GORD symptoms.

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This study compares two heartburn medications (rabeprazole and esomeprazole) for adults who have had heartburn with or without acid reflux for 3 months or longer. Participants must have had heartburn on more than 3 days in the past week. You cannot join if you need an endoscopy soon, have significant stomach or intestinal disease, or are pregnant.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Subjects will be randomised to receive oral treatment with either 20mg Rabeprazole Sodium (PARIET), 20mg Esomeprazole (NEXIUM) or 40mg Esomeprazole (NEXIUM) once daily for 4 weeks. There is no control

Subjects will be randomised to receive oral treatment with either 20mg Rabeprazole Sodium (PARIET), 20mg Esomeprazole (NEXIUM) or 40mg Esomeprazole (NEXIUM) once daily for 4 weeks. There is no control group all treatments are currently marketing active interventions.

Locations(1)

Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12607000006448